Fibrosis Small Molecule Program

About Ocean Biomedical

Ocean Biomedical is a biopharmaceutical company focused on translating groundbreaking academic research into novel therapeutics. Its strategy involves in-licensing and developing a diversified pipeline of drug candidates targeting oncology, fibrosis, and infectious diseases. The company went public via a SPAC merger in 2023, providing capital to advance its lead programs into clinical development. Its approach centers on identifying and validating new biological pathways to create first-in-class or best-in-class treatments.

Therapeutic Areas